X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Kevin Haninger

Kevin Haninger Kevin Haninger, PhD, is Deputy Vice President, International Advocacy at the Pharmaceutical Research and Manufacturers of America (PhRMA). Kevin leads PhRMA’s international health policy advocacy including development of strategy, analysis, and policy positions on the cost and value of medicines, government pricing and reimbursement, and health technology assessment. Prior to joining PhRMA, Kevin was Senior Economist in the Office of the Secretary at the U.S. Department of Health and Human Services.

Recent Posts

In the OECD other health care services will be ten times prescription medicine spending growth over next decade

By Kevin Haninger  |    June 14, 2017
Now more than ever, innovative therapies are transforming care and providing cures for patients fighting life-threatening diseases.  In the midst of this medical progress, other health care...   Read More

Foreign government price setting by any name harms innovation and access to medicines

By Kevin Haninger  |    June 6, 2017
In an effort to contain health care spending, some foreign governments mandate prices for innovative medicines at levels below the value they provide to patients, health care systems, and the...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates